Compare Illumina, Inc. (ILMN) vs Jumia Technologies AG - ADR (JMIA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Jumia Technologies AG - ADR — how do they compare? Illumina, Inc. trades at $275.85 (market cap $39.95B), while Jumia Technologies AG - ADR trades at $6.18 (market cap $865.90M). The key difference: Illumina, Inc. is far larger — about 46.1× Jumia Technologies AG - ADR's market cap, and Illumina, Inc. is trading nearer its 52-week high, Jumia Technologies AG - ADR nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Illumina, Inc. for 83 Days and Jumia Technologies AG - ADR for 28 Days on average.
| ILMN | JMIA | |
|---|---|---|
Market Cap | $39.95B | $865.90M |
Volume | 3,169,503 | 1,695,227 |
Sector | Health | Consumer Cyclical |
52-Week High | $293.69 | $14.60 |
52-Week Low | $91.00 | $5.69 |
Typical Hold Time | 83 Days | 28 Days |
Enterprise Value | $41.31B | $831.54M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $271.02, up 1.22% and near its 52-week high, reflecting strong momentum. The stock exhibits a bullish technical trend with recent earnings beats and a positive analyst consensus. Revenue for 2025 was $4.34B with net income of $850M, marking a significant profit margin recovery. Cash flow from operations remains robust at $1.08B, supporting financial stability. Inclusion in the S&P 500 and focus on AI-driven genomics growth are key catalysts.
Outlook is positive given earnings momentum and strategic initiatives, but risks include valuation premiums and competitive pressures. The stock offers growth exposure to genomic innovation, though investors should monitor execution on AI integration and margin sustainability. Analyst price targets suggest moderate upside from current levels, with consensus at $241.00.
JMIA stock trades at $6.315, down 6.31% today, amid a bearish technical signal. The company reported revenue of $188.93M in 2025 with a net loss of $61.55M, though losses are narrowing year-over-year. Analyst consensus is bullish with a $12.00 price target, and recent news highlights a $50M capital raise and progress toward EBITDA breakeven by year-end 2026.
The outlook hinges on JMIA achieving profitability targets, with upside potential from analyst targets but risks from persistent losses and high valuation multiples. Execution on cost control and African e-commerce growth are critical for stock performance, while cash flow volatility remains a concern.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Jumia Technologies AG - ADR
Jumia Technologies AG is the pan-African e-commerce platform. The company's platform consists of a marketplace, which connects sellers with consumers. Its logistics service enables the shipment and delivery of packages from sellers to consumers, and the company's payment service facilitates transactions among participants active on its platform in selected markets. Jumia generates revenue from Sales of goods, Commissions, Fulfillment, Value-added services, and Marketing & Advertising. Its geographical segments are West Africa, North Africa, East & South Africa, Europe, and United Arab Emirates. The firm generates most of its revenue from the West Africa segment.
Read more on JMIA →
